FRISCO, Texas--(BUSINESS WIRE)--Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today it was selected as a limited distribution partner for VYVGART™ (efgartigimod alfa-fcab) by argenx SE. VYVGART was approved by the U.S. Food & Drug Administration (FDA) on December 17, 2021 for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
VYVGART is the first and only FDA-approved drug of its type, a neonatal Fc receptor (FcRn) blocker, approved to treat AChR+ gMG. gMG is a severe and chronic autoimmune disease that affects neuromuscular transmission and creates a fluctuating weakness of the voluntary muscles.
Effective immediately, Soleo Health is able to manage and administer VYVGART intravenously in patients’ homes or its ambulatory infusion centers nationwide. Patients are supported through Soleo Health’s Myasthenia Gravis Therapeutic Care Management Center (TCMC). The TCMC is staffed with specially trained interdisciplinary teams, comprising highly-experienced therapy care pharmacists, registered nurses, reimbursement specialists and patient care ambassadors dedicated to supporting patients living with myasthenia gravis.
Soleo Health has extensive experience administering specialty pharmaceuticals for rare and ultra-rare diseases, a knowledgeable and talented TCMC team, and a strong commitment to enhancing patient experiences and outcomes. Additionally, Soleo Health offers differentiated capabilities through its ability to collect real-world data and generate intelligent outcomes from VYVGART patients with its exclusive and proprietary clinical outcomes program, SoleMetrics®.
According to the Myasthenia Gravis Foundation of America, gMG affects approximately 36,000 to 60,000 people in the U.S. However, gMG remains underdiagnosed in patients, and its prevalence is likely higher.
“Soleo Health is at the forefront of bringing revolutionary specialty pharmaceuticals to patients nationwide with this new partnership with argenx. Our ever-growing limited drug distribution portfolio continues to expand as we are increasingly recognized for our capabilities, particularly within the autoimmune and neurology arenas,” said Drew Walk, Soleo Health chief executive officer.
Patients or providers interested in learning more about Soleo Health’s administering of VYVGART should contact its dedicated gMG Therapeutic Care Management Center at: MGTherapy@SoleoHealth.com or toll-free 844.503.0912.
About Soleo Health
Frisco, Texas-based Soleo Health is an innovative national provider of complex specialty pharmacy services administered in the home or alternate sites of care. Soleo Health’s interdisciplinary team, comprised of experienced clinical pharmacists and registered nurses, utilizes a consistent patient management process, which leads to quantifiable clinical and economic value while improving the patient experience.
Soleo Health operates 21 locations throughout the U.S. with national nursing coverage and pharmacy licensure in 50 states and is accredited by URAC, ACHC with Distinction in Rare Disease and Orphan Drugs and The Joint Commission.
Visit www.soleohealth.com or connect with Soleo Health on LinkedIn, Facebook and Twitter for more information.
